Cas:773850-91-2 Drimiopsin D manufacturer & supplier

Chemical Name:Drimiopsin D

CAS.NO:773850-91-2

Synonyms:1,3,6-Trihydroxy-4,5-dimethoxy-8-methyl-9H-xanthen-9-one;9H-Xanthen-9-one, 1,3,6-trihydroxy-4,5-dimethoxy-8-methyl-;1,3,6-Trihydroxy-2,5-dimethoxy-8-methyl-9H-xanthen-9-one;9H-Xanthen-9-one, 1,3,6-trihydroxy-2,5-dimethoxy-8-methyl-

Molecular Formula:C₁₆H₁₄O₇

Molecular Weight:318.278

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:602.4±55.0 °C at 760 mmHg

Density:1.5±0.1 g/cm3

Index of Refraction:1.667

PSA:109.36000

Exact Mass:318.073944

LogP:0.86

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1,3,6-Trihydroxy-4,5-dimethoxy-8-methyl-9H-xanthen-9-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,9H-Xanthen-9-one, 1,3,6-trihydroxy-2,5-dimethoxy-8-methyl- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,3,6-Trihydroxy-4,5-dimethoxy-8-methyl-9H-xanthen-9-one Use and application,1,3,6-Trihydroxy-4,5-dimethoxy-8-methyl-9H-xanthen-9-one technical grade,usp/ep/jp grade.

Related News: China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases. Drimiopsin D manufacturer With the global industrial division of labor and the change in the business model of multinational pharmaceutical companies, the outsourced market for patented drug substances will further expand. Drimiopsin D supplier Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday. Drimiopsin D vendor China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases. Drimiopsin D factory In these situations, the API is not a single substance but the culmination of various ingredients.